Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Silence Therapeutics plc (SLNCF)
London, GB
Silence Therapeutics plc, a biotechnology firm headquartered in London, United Kingdom, is dedicated to the discovery and advancement of pioneering ribonucleic acid (RNA) therapeutics. Its research and development efforts span key areas such as blood disorders, cardiovascular health, and other uncommon and metabolic ailments. Central to the company's approach is its proprietary mRNAi GalNAc Oligonucleotide Discovery platform, meticulously crafted to precisely target specific disease-causing genes, predominantly within the liver. This mechanism involves creating short interfering RNA (siRNA) molecules that activate the body's intrinsic RNA interference pathway, effectively breaking down messenger RNA (mRNA) sequences responsible for producing particular disease-associated proteins inside cells. Silence Therapeutics is actively developing a pipeline of therapeutic candidates. This includes SLN360, currently in Phase I clinical trials for the treatment of cardiovascular disease characterized by elevated lipoprotein levels. Furthermore, SLN124 is progressing through Phase I clinical trials for both non-transfusion dependent thalassemia and myelodysplastic syndrome, with ongoing development also focused on polycythemia vera. The company has forged strategic partnerships to broaden its reach and capabilities. It collaborates with AstraZeneca PLC to identify, develop, and commercialize small interfering RNA therapeutics addressing cardiovascular, renal, metabolic, and respiratory conditions. Another alliance is with Mallinckrodt Pharma IP Trading DAC, centered on developing and marketing RNAi drug targets designed to inhibit the complement cascade in various complement-mediated disorders. Additionally, Silence Therapeutics is working with Hansoh Pharmaceutical Group Company Limited to develop siRNAs for three confidential targets, utilizing its mRNAi GOLD platform. The organization, which operated as SR Pharma plc until its rebranding in May 2007, continues its mission under the name Silence Therapeutics plc.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -44.77% | -44.77% | -44.13% | -9.22% | -9.22% | -27.38% | +49.74% | -41.90% | -82.91% | -13.02% | -41.90% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 1 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Biotechnology: +1.6%-98.7% Q1'26: +197.2% (vs Q1'25)
-
EPS growth Biotechnology: +29.7%-90.9% Q1'26: +45.0% (vs Q1'25)
-
FCF margin FCF growth · Biotechnology: +16.2%-13,284.7% Q1'26: -3,697.4% (vs Q1'25)
-
EBIT margin Biotechnology: +0.0%-14,720.9% Q1'26: -3,565.4% (vs Q1'25)
-
ROIC Biotechnology: -16.1%— Q1'26: +293.0% (vs Q1'25)
-
Share dilution Biotechnology: -3.4%+2.1% ★ Q1'26: +0.0% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Biotechnology: 0.16×0.00× Q1'26: 0.00× (vs Q1'25)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Dec 2018 actual |
Dec 2019 actual |
Dec 2020 actual |
Dec 2021 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 1 Rev. Ana. 2 EPS Ana. |
Dec 2027 1 Rev. Ana. 1 EPS Ana. |
Dec 2028 1 Rev. Ana. 1 EPS Ana. |
Dec 2029 1 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
—
est: 17.88M (-100.0%)
|
244.0K
est: 2.42M (-89.9%)
|
5.48M
est: 12.39M (-55.8%)
|
12.42M
est: 20.79M (-40.3%)
|
17.50M
est: 28.70M (-39.0%)
|
25.38M
est: 36.34M (-30.2%)
|
43.26M
est: 24.78M (+74.6%)
|
559.0K
est: 8.22M (-93.2%)
|
11.93M
11.93M – 11.93M
+45.2% YoY
|
19.06M
19.06M – 19.06M
+59.7% YoY
|
69.95M
69.95M – 69.95M
+267.1% YoY
|
160.62M
160.62M – 160.62M
+129.6% YoY
|
| EBITDA |
-20.17M
est: -17.88M (-12.8%)
|
-22.36M
est: -2.42M (-824.4%)
|
-35.53M
est: -12.39M (-186.7%)
|
-45.42M
est: -20.79M (-118.5%)
|
-50.62M
est: -28.70M (-76.4%)
|
-49.78M
est: -36.34M (-37.0%)
|
-48.99M
est: -24.78M (-97.7%)
|
-81.74M
est: -8.22M (-894.8%)
|
-11.93M
-11.93M – -11.93M
-45.2% YoY
|
-19.06M
-19.06M – -19.06M
-59.7% YoY
|
-69.95M
-69.95M – -69.95M
-267.1% YoY
|
-160.62M
-160.62M – -160.62M
-129.6% YoY
|
| EBIT |
-20.57M
est: -17.88M (-15.0%)
|
-22.84M
est: -2.42M (-844.4%)
|
-36.03M
est: -12.39M (-190.7%)
|
-45.85M
est: -20.79M (-120.6%)
|
-48.79M
est: -28.70M (-70.0%)
|
-50.28M
est: -36.34M (-38.4%)
|
-49.58M
est: -24.78M (-100.1%)
|
-82.29M
est: -8.22M (-901.5%)
|
-11.93M
-11.93M – -11.93M
-45.2% YoY
|
-19.06M
-19.06M – -19.06M
-59.7% YoY
|
-69.95M
-69.95M – -69.95M
-267.1% YoY
|
-160.62M
-160.62M – -160.62M
-129.6% YoY
|
| Net Income |
-18.41M
est: -132.5K (-13,791.3%)
|
-19.58M
est: -37.59M (+47.9%)
|
-32.55M
est: -34.60M (+5.9%)
|
-39.41M
est: -51.24M (+23.1%)
|
-40.49M
est: -20.19M (-100.5%)
|
-43.27M
est: -20.63M (-109.8%)
|
-45.31M
est: -33.90M (-33.7%)
|
-88.61M
est: -44.41M (-99.5%)
|
-36.46M
-37.49M – -35.43M
+17.9% YoY
|
-34.23M
-34.23M – -34.23M
+6.1% YoY
|
-20.46M
-20.46M – -20.46M
+40.2% YoY
|
-22.10M
-22.10M – -22.10M
-8.0% YoY
|
| SGA |
10.83M
est: 26.06M (-58.4%)
|
9.64M
est: 3.52M (+173.6%)
|
13.98M
est: 18.06M (-22.6%)
|
20.01M
est: 30.29M (-33.9%)
|
19.21M
est: 41.83M (-54.1%)
|
20.57M
est: 52.95M (-61.2%)
|
26.88M
est: 218.61M (-87.7%)
|
22.34M
est: 72.49M (-69.2%)
|
105.25M
105.25M – 105.25M
+45.2% YoY
|
168.12M
168.12M – 168.12M
+59.7% YoY
|
617.14M
617.14M – 617.14M
+267.1% YoY
|
1.42B
1.42B – 1.42B
+129.6% YoY
|
| EPS |
-0.26
est: 0.00 (-27,119.4%)
|
-0.26
est: -0.27 (+4.0%)
|
-0.40
est: -0.25 (-60.4%)
|
-0.44
est: -0.37 (-19.2%)
|
-0.52
est: -0.15 (-257.3%)
|
-0.39
est: -0.15 (-162.4%)
|
-0.33
est: -0.24 (-37.9%)
|
-0.63
est: -0.31 (-101.0%)
|
-0.26
-0.26 – -0.25
+17.9% YoY
|
-0.24
-0.24 – -0.24
+6.1% YoY
|
-0.14
-0.14 – -0.14
+40.2% YoY
|
-0.16
-0.16 – -0.16
-8.0% YoY
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-07 | C- | 1/5 | 2/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-20 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-16 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
| # | Reporting person | Amount owned | % of class | Sole voting | Shared voting | Sole dispositive | Shared dispositive | Type | Citizenship | Filing date | SEC filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Robert Keith | 12.29M | 13.70% | 12.29M | — | 12.29M | — | IN | United Kingdom | 2021-02-17 | ↗ |
| 2 | Lombard Odier Asset Management (USA) Corp | 10.42M | 11.60% | — | 10.42M | — | 10.42M | IA, OO | Delaware | 2022-02-10 | ↗ |
| 3 | Robert Quested | 7.62M | 8.50% | 7.62M | — | 7.62M | — | IN | Gibraltar | 2021-02-17 | ↗ |
| 4 | TCG Crossover Management, LLC | 6.31M | 5.90% | 6.31M | — | 6.31M | — | IA | Delaware, United States | 2022-08-19 | ↗ |
| 5 | David Kroin | 5.85M | 5.44% | — | 5.85M | — | — | HC, IN | United States | 2022-08-22 | ↗ |
| 6 | Deep Track Biotechnology Master Fund, Ltd. | 5.85M | 5.44% | — | 5.85M | — | — | CO | United States | 2022-08-22 | ↗ |
| 7 | Deep Track Capital, LP | 5.85M | 5.44% | — | 5.85M | — | — | IA, OO | United States | 2022-08-22 | ↗ |
| 8 | GOLDMAN SACHS & CO. LLC | 4.83M | 5.40% | — | 13.00 | 4.83M | 4.83M | BD, IA, OO | Delaware | 2022-01-27 | ↗ |
| 9 | THE GOLDMAN SACHS GROUP, INC. | 4.83M | 5.40% | — | 13.00 | 4.83M | 4.83M | HC, CO | Delaware | 2022-01-27 | ↗ |
| 10 | Richard Ian Griffiths | 709.00 | 27.00% | 709.00 | — | 709.00 | — | IN | Jersey, Channel Islands | 2022-06-15 | ↗ |
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
This company is not held by any ETF in our universe.
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
| # | Year | Executive | Salary | Bonus | Stock award | Option award | Incentive | Other | Total | % Stock- based |
Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 2024 | Craig Tooman Chief Executive Officer | 618.8K | — | — | 2.69M | 352.7K | 32.6K | 3.69M | 72.82% | ↗ |
| 2 | 2024 | Rhonda Hellums Executive Vice President, Chief Financial Officer | 466.0K | — | — | 985.7K | 188.5K | 22.6K | 1.66M | 59.28% | ↗ |
| 3 | 2024 | Steven Romano, M.D. Executive Vice President, Chief of Research and Development | 465.8K | — | — | 929.8K | 188.4K | 8.3K | 1.59M | 58.40% | ↗ |
| 4 | 2023 | Craig Tooman Chief Executive Officer | 589.4K | — | — | 7.64M | 840.9K | 33.4K | 9.10M | 83.92% | ↗ |
| 5 | 2023 | Rhonda Hellums Executive Vice President, Chief Financial Officer | 430.5K | — | — | 2.22M | 409.5K | 21.7K | 3.08M | 72.07% | ↗ |
| 6 | 2023 | Steven Romano, M.D. Executive Vice President, Chief of Research and Development | 322.5K | — | — | 1.62M | 193.5K | 3.7K | 2.14M | 75.70% | ↗ |
| 7 | 2022 | Craig Tooman Chief Executive Officer | 557.1K | — | — | 5.26M | 136.0K | 81.9K | 6.04M | 87.17% | ↗ |
| 8 | 2022 | Rhonda Hellums Executive Vice President, Chief Financial Officer | 404.0K | — | — | 1.89M | 69.2K | 20.2K | 2.38M | 79.30% | ↗ |
Proxy statements
Recent SEC filings
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Rhonda L. Hellums | Executive VP, CFO, Secretary & Executive Director | 512.9K | female |
| Steven J. Romano | Executive Vice President and Chief Research & Development Officer | 496.7K | — |
| Iain Gladstone Ross | Interim CEO & Chairman of the Board | 481.9K | male |
| Gianine Esposito | Chief Human Resources Officer | — | female |
| Curtis Rambaran | Chief Medical Officer | — | male |
| Jaimin Shah | SVP & General Counsel | — | male |
| Marie Wikstrom Lindholm | Chief Scientific Officer | — | — |
| Gem Gokmen Hopkins | Head of IR & Corporate Communications | — | female |
| Gabriel | Chief Technical Operations Officer | — | male |
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for SLNCF
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
